<< Workshop to address cultural diversity and ethnicity in healthcare | Recent progress of Delcath Systems in drug delivery platform reported >>
Read in | English | 日本語 | 한국어

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

Published on November 19, 2009 at 7:13 AM · No Comments

SAFEBRIDGE® CONSULTANTS, INC. (“SafeBridge”), headquartered in Mountain View, California, has announced that ScinoPharm Taiwan Limited (”ScinoPharm”) in Tainan, Taiwan has met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”). The SafeBridge Potent Compound Safety Certification applies only to specific laboratories and manufacturing areas at the Tainan site for research, development and manufacture of potent compounds.

SafeBridge conducted a 60-element review of programs, procedures, containment and control of the active pharmaceutical ingredients at the company’s site. Based on the quantitative results of the Potent Compound Safety Certification program, SafeBridge certifies that ScinoPharm meets current industry standards for the safe handling of potent APIs in the identified areas.

Source SAFEBRIDGE CONSULTANTS, INC.

Posted in: Pharmaceutical News

Tags: , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading